Enoxaparin for VTE thromboprophylaxis for inpatient rehabilitation care: assessment of the standard fixed dosing regimen

doi:10.21203/rs.3.rs-2605384/v1

Download PDF

Research Article

Enoxaparin for VTE thromboprophylaxis for inpatient rehabilitation care: assessment of the standard fixed dosing regimen

https://doi.org/10.21203/rs.3.rs-2605384/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 10 Jan, 2024

Read the published version in BMC Pharmacology and Toxicology →

You are reading this latest preprint version

Background. We aimed to examine the efficiency of fixed daily dose enoxaparin (40 mg) thromboprophylaxis strategy for patients undergoing inpatient rehabilitation.

Methods. This was an observational, prospective, cohort study that included 63 hospitalized patients undergoing rehabilitative treatment following sub-acute ischemic stroke (SAIS) or spinal cord injury (SCI), with an indication for thromboprophylaxis. Anti-Xa level measured three hours post-drug administration (following three consecutive days of enoxaparin treatment or more) was utilised to assess in vivo enoxaparin activity. An anti-Xa level between 0.2–0.5 U/ml was considered evidence of effective antithrombotic activity.

Results. We found sub-prophylactic levels of anti-Xa (< 0.2 U/ml) in 19% (12/63). Results were within the recommended prophylactic range (0.2–0.5 U/ml) in 73% (46/63) and were supra-prophylactic (> 0.5 U/ml) in 7.9% (5/63) of patients. Anti-Xa levels were found to inversely correlate with patients’ weight and renal function as defined by creatinine clearance (CrCl) (p < 0.05).

Conclusions. Our study confirmed that a one-size-fits-all approach for venous thromboembolism (VTE) prophylaxis may be inadequate for rehabilitation patient populations. The efficacy of fixed-dose enoxaparin prophylaxis is limited and may be influenced by renal function and weight. This study suggests that anti-Xa studies and prophylactic enoxaparin dose adjustments should be considered in certain patients, such as those who are underweight, overweight and or have suboptimal renal function.

Trial Registration. No. NCT103593291, registered August 2018.

Enoxaparin

Rehabilitation

Venous pulmonary embolism

Venous thromboembolism

Clinicians should be aware that fixed dose enoxaparin prophylaxis will only provide adequate therapeutic response for a proportion of rehabilitation patient patients.
The efficacy of fixed-dose enoxaparin prophylaxis is limited and may be influenced by renal function and weight.
A personalized approach to VTE prophylaxis that includes anit-Xa studies and prophylactic dose adjustments should be considered in certain patients, such as those who are underweight, overweight and or have suboptimal renal function.
More studies are required to investigate the interaction of weight and creatinine in order to establish VTE prophylactic dosing guidelines for specific rehabilitation populations.

Venous thromboembolism (VTE), comprising deep venous thrombosis (DVT) and venous pulmonary embolism (PE), is a common and preventable complication in patients undergoing rehabilitation, which can result in significant morbidity and death [1–7]. Prolonged bed rest (> 14 days) is associated with a five-fold increased risk of developing DVT [4]. The American Society of Haematology (ASH) 2018 guidelines for the management of VTE states that the risk of VTE persists for 45–60 days following discharge from acute hospitalisation [8]. The rate of DVT has been reported as high as 33% among people undergoing rehabilitation for a variety of conditions [2]. The current study focused on two common clinical rehabilitation in-patient scenarios: patients recovering from acute ischemic stroke (AIS) or recovering from acute spinal cord injury (SCI). There is a large body of evidence that describes the prevalence of VTE in these areas [1, 3, 9–12]. Depending on the diagnostic methods and time of evaluation, the incidence of DVT without prophylaxis is 20–50% following stroke and 60–80% following SCI [1, 13]. Risk factors for developing DVT in these patients include immobility, older age (> 65 years), female gender, obesity (body mass index (BMI) ≥25kg/m²), active cancer and muscle weakness [1, 3, 9].

The symptoms of DVT and pulmonary embolism (PE) are often non-specific, especially in patients undergoing rehabilitation who may under-report symptoms due to aphasia, cognitive impairment or altered conscious states [2]. VTE often presents as simply fever and leg edema [14]. Due to the difficulty associated with diagnosis, administration of routine prophylactic therapy is recommended by multiple guidelines for patients hospitalized for rehabilitation for a variety of diagnoses [8, 10, 15]. VTE prevention therapy for survivors of ischemic stroke is recommended for the duration of in-patient rehabilitation or until the stroke survivor regains mobility [3]. Based on the severity of the SCI, low molecular weight heparin (LMWH) are recommended for up to 24 weeks after injury [13].

Enoxaparin, a LMWH, is considered the standard prophylactic treatment for patients undergoing rehabilitation for AIS or SCI [3, 8, 10]. Enoxaparin is a convenient option for thromboprophylaxis due to its predictability in regards to dose response, long half-life and lower risk of bleeding for a given antithrombotic effect [16]. Several doses and treatment regimens have been proposed; however, a fixed dose of 40mg once daily is the accepted, prevailing approach and is considered the standard prophylactic dose [12, 17, 18]. In clinical practice, a fixed dose regimen is frequently used, with the exception of patients who are underweight, obese, pregnant, or suffering from renal insufficiency (creatinine clearance (CrCl) < 30 ml/min) [19, 20].

The anti-factor Xa (anti-Xa) assay is a functional assay that helps measure antithrombin (AT)-catalyzed inhibition of factor Xa by Unfractionated Heparin (UFH) and direct inhibition of factor Xa (FXa) by enoxaparin. As a result, the anti-Xa level reflects the in-vivo pharmacological activity of enoxaparin. For prevention of DVT/PE, steady state peak Anti-Xa activity measured three hours post-drug administration following three consecutive days of enoxaparin treatment or more is considered to be 0.2–0.5 IU/ml [21, 22].

Several studies examining anti-Xa activity with the fixed enoxaparin prophylactic dosing have reported shortcomings for several clinical scenarios. For example, critically ill, trauma and burn, plastic surgery, renal and oncology patients often demonstrate low plasma anti-factor Xa (anti-Xa) levels, suggesting inadequate prophylaxis (sub/supra prophylaxis) and which may lead to an increased risk of thrombotic and bleeding events [17–19, 21, 23–28]. To the best of our knowledge, similar investigations have not been reported in the literature for patients in a rehabilitation setting.

The current study was devised to examine the efficiency of fixed dose enoxaparin as a thromboprophylaxis strategy for patients recovering from SAIS or SCI admitted to a rehabilitation hospital. The goal of this study was to evaluate in-vivo enoxaparin activity in these patients, and to evaluate the influence of co-variables (e.g., renal function, weight) on the outcome of this treatment strategy.

This study was an observational, cross sectional, prospective cohort study approved by the Institutional Ethics Committee on Human Research at the Loewenstein Rehabilitation Hospital (No. NCT103593291). Consecutive patients hospitalized for rehabilitation following SAIS or SCI were recruited after giving consent to participate in the study.

Prophylactic treatment with subcutaneous injection of LMWH (enoxaparin 40 mg once daily) was initiated during pre-rehab acute care. It was re-evaluated on admission to our rehabilitation hospital and continued where clinically necessary [3, 10]. Inclusion criteria included: age 20–80 years, hospitalization for rehabilitation following AIS or SCI, indication for thromboprophylaxis due to major restriction of mobility and no elevated risk of bleeding. The exclusion criteria included: patients in whom there was a severe risk of bleeding, obesity (> 150kg), low weight (< 45kg for women, 57kg for men), renal insufficiency (CrCl < 30ml/min) and patients receiving anticoagulant therapy for concomitant pathologies (e.g. atrial fibrillation). For patients recovering from SAIS, exclusion criteria also included hemorrhagic stroke, hemorrhagic transformation of stroke or bleeding into another site.

Data Collection

All information was obtained from the patients’ electronic or hardcopy files. The following variables were recorded on admission and discharge: patient characteristics (age, gender, weight, height and diagnosis), days from stroke onset to admission to rehabilitation hospital and length of stay in rehabilitation hospital. A specific data collection form was developed by the research coordinator. Trained research associates, who were familiar with the process of chart review, extracted information from charts using the form provided.

Blood sample for peak plasma levels of anti-Xa activity were drawn three hours post-enoxaparin administration (after a minimum of three days of treatment). Blood samples were collected in 3.2% sodium citrate tubes and centrifuged at twice 1500g for 15min and stored at − 70◦C. At this time, blood sample for serum creatinine (CR) was collected as well. Renal function was assessed by calculating CrCl according to the Cockcroft and Gault equation [29].

Plasma samples were tested for the chromogenic anti-Xa activity assay with HemosIL Liquid anti-Xa (Instrumentation Laboratory, Bedford, USA) reagent using the analyzer system ACL TOP Family 500/550 (Instrumentation Laboratory) [30]. The method is based on adding the patient’s plasma to a test tube containing FXa reagent and a chromogenic substrate to FXa. If the patient’s plasma contains enoxaparin, a complex of the drug will be formed with the patients ATIII and FXa inhibition will occur. The remaining free FXa will bind to the chromogenic substrate. The color released is measured and is inversely related to the amount of anti-Xa present in the plasma. The anti-Xa activity measurement result was a surrogate marker of enoxaparin activity (IU/ml) [30].

The target anti-Xa level was defined as 0.2–0.5 U/ml and results were divided into three categories: LOW-sub-prophylactic (< 0.2 U/ml), NORMAL-prophylactic (0.2–0.5 U/ml) and HIGH-supra-prophylactic (> 0.5 U/ml).

Statistical analysis

Data were evaluated by SPSS software for Windows version 27.0 (SPSS Inc., Chicago, IL, USA). Univariate statistics included t test for independent groups to compare between the two studies. One-way ANOVA was used to compare between the three groups of anti-Xa (LOW, NORMAL, HIGH) for continuous variables. Pearson’s Chi-square test was used to compare categorical variables. Values were reported as mean ± SEM. Pearson’s correlation test was used to assess correlations. Significance level was set at p < 0.05. Multiple regression was used as multivariate analysis. The dependent variable was the level of anti-Xa and the independent variables were the significant variables from the univariate analysis.

From August 2018 to November 2019, all patients hospitalized for rehabilitation following SAIS or SCI and receiving SC enoxaparin 40mg/day thromboprophylaxis were considered for inclusion. A total of 63 patients (31 SAIS and 32 SCI) were enrolled in the study (all eligible candidates who gave informed consent). Patient characteristics of the study cohorts are shown in Table 1. Most of the patients were men (70%), with a mean age of 59 years, a median creatinine clearance of 93 ml/min and a median total body weight of 75 kg. Patients in the SCI group were significantly younger than the SAIS group (mean SAIS 63.6 years, SCI 54.7 years, p = 0.01). The percentage of patients with type 2 diabetes mellitus was significantly higher in the SAIS group (p = 0.002). No other significant differences were found between the groups. Neither major bleeding episodes nor VTE-related events were recorded during the hospitalization period.

Table 1

Characteristics of study participants
	All (n = 63)	SAIS (n = 31)	SCI (n = 32)	p
Age (years) (mean)	59.1 ± 14	63.6 ± 7.7	54.7 ± 17.1	0.01
Male (% of patients)	44 (70%)	23 (74%)	21 (66%)	NS
Height (m) (Median)	1.7 (0.12)	1.69 (0.12)	1.7 (0.13)	NS
Total body weight (kg) (median)	75 (21)	77 (20)	73 (14.9)	NS
BMI (kg/m²) (median)	26 (5.46)	27.6 (4.57)	26.2 (6.17)	NS
Diabetes (% of patients)	30 (48%)	21 (68%)	9 (28%)	0.002
Current smoker (% of patients)	20 (32%)	13 (42%)	7 (22%)	NS
Creatinine (mg/dl) (mean)	0.9 ± 0.2	0.9 ± 0.1	0.8 ± 0.2	NS
CrCl (ml/min) (mean)	96.9 ± 29.3	90.2 ± 21.2	103.3 ± 34.6	NS

Note

Quantitative data are expressed as median and interquartile range or mean±standard deviation as appropriate.

BMI=body mass index; CrCl=creatinine clearance computed according to the Cockroft-Gault formula

Mean peak anti-Xa levels were 0.31 ± 0.11 IU/ml for the combined study group, 0.33 ± 0.95 IU/ml for the SAIS cohort and 0.29 ± 0.13 for the SCI cohort (p = 0.199). The results showed that only 73% (46/63) of the patients studied had anti-Xa activity within the recommended prophylactic range (0.2–0.5 U/ml). In the remaining 27% of patients, enoxaparin anti-Xa activity levels were outside the recommended range, either sub-prophylactic anti-Xa activity (< 0.2 U/ml) in 19% (12/63) of patients or supra-prophylactic (> 0.5 U/ml) in 7.9% (5/63).

Univariate analysis of patient-related covariates demonstrated a significantly negative correlation between weight (r=-0.6, p < 0.0001), BMI (r=-0.42, p < 0.001) and CrCl (r=-0.35, p < 0.004) with anti-Xa activity. (Table 2, Figs. 1 and 2) Analysis of variance when anti-Xa activity was grouped into three categories; sub-prophylactic (< 0.2 U/ml), prophylactic (0.2–0.5 U/ml) and supra-prophylactic (> 0.5 U/ml), demonstrated a negative correlation between weight and anti-Xa levels categories (Fig. 3 ).

Table 2

Correlation of patient-related covariates and anti-Xa activity
Anti-Xa activity
Age (years)	Pearson Correlation	0.127
	Sig. (2-tailed)	0.322
	N	63
BMI (kg/m²)	Pearson Correlation	− .422^**
	Sig. (2-tailed)	0.001
	N	63
CR (mg/dl)	Pearson Correlation	-0.206
	Sig. (2-tailed)	0.105
	N	63
Weight (kg)	Pearson Correlation	− .602^**
	Sig. (2-tailed)	0.0001
	N	63
CrCl (ml/min)	Pearson Correlation	− .355^**
	Sig. (2-tailed)	0.004
	N	63
Height (m)	Pearson Correlation	− .353^**
	Sig. (2-tailed)	0.005
	N	63
Note:
** Correlation is significant at the 0.01 level (2-tailed)

The present study assessed a cohort of 63 rehabilitation patients recovering from either SAIS or SCI. Only 73% patients (46/63) receiving fixed-dose prophylactic enoxaparin 40mg achieved the recommended therapeutic target. More than one-quarter of patients (27%) in our study were found to be outside the recommended range for anti-Xa activity. Twelve patients (19%) had sub-prophylactic anti-Xa activity and five patients (7.9%) had supra-prophylactic levels of anti-Xa. Weight and CrCl were found to be the most influential factors on anti-Xa activity. The data showed a negative correlation between anti-Xa levels; as weight increased, the level of anti-Xa activity decreased to the sub-prophylactic range whereas lower CrCl correlated with supra-prophylactic anti-Xa activity for renal function. Being within the recommended therapeutic range for anti-Xa is especially important for these clinical sub-groups, since patients recovering from SAIS or SCI are already at an increased risk of developing VTE or bleeding events compared to the general population.

The product information of enoxaparin states that there is an increase in exposure of enoxaparin with renal impairment and such patients should be monitored for signs of bleeding. In patients with renal impairment (CrCl < 30ml/min), exposure to enoxaparin is significantly increased and dose adjustment is recommended [31]. In addition, the safety and efficacy of a fixed daily dose of 40 mg in patients with obesity (BMI > 30) has not been determined and there is no consensus for dose adjustment. Similarly, dose adjustment is controversial for patients who are underweight. Underweight individuals may have increased exposure to enoxaparin and, therefore, a higher risk of bleeding while obese individuals are at a higher risk of thromboembolism [31]. Our study demonstrates that weight and CrCl do indeed correlate with anti-Xa activity. Nonetheless, this correlation can lead to non-therapeutic activity even in patients whose weight and creatine are within the recommended ranges.

Our study confirms previous reports showing that fixed-dose prophylactic regimens are often unsuitable for many patients [17–19, 21, 23, 24, 26, 27, 32, 33]. Similar to our results, Maurice-Dror et al recently reported that, among a cohort of 76 oncology patients, 16 (21%) demonstrated sub-prophylactic anti-Xa activity (< 0.2 U/ml). These authors concluded that a substantial number of cancer patients receiving enoxaparin prophylaxis are undertreated, with weight and plasma pre-treatment coagulation parameters being influential factors [21]. Several other studies have also shown that different dosing strategies should be considered in patients who are underweight or overweight [20, 28, 34–36].

However, studies in different settings focusing on patients in trauma intensive care have reported higher percentages of patients with subtherapeutic anti-Xa activity [17, 32, 33, 37]. The ATLANTIC study, published by Rakhra et al, investigated anti-Xa levels in trauma intensive care patients hospitalized following traumatic brain injury (TBI) or SCI. In this study, 12/25 (48%) patients demonstrated low peak anti-Xa activity (≤0.2 U/ml) with fixed-dose prophylactic enoxaparin. The study concluded that high-risk critically ill patients receiving prophylactic enoxaparin often show inadequate anti-Xa activity and further investigation is required concerning dose optimisation [17].

There are several limitations to our study, including the small sample size. In addition, the data is only valid for the sub-groups tested and, while it may be logical to extrapolate to other groups, more research is required to ascertain the relevance of these findings. During the study period, there were no recorded episodes of major bleeding or VTE-related events. However, the study was not designed for a systematic evaluation of these events. Assessing VTE events can be complicated, as different assessments give different analyses. Moreover, VTE and bleeding events are relatively rare, and it would take a large number of patients to view statistically relevant results. Monitoring anti-Xa allows us to evaluate efficacy with a smaller cohort of patients.

Our study demonstrates that a one-size-fits-all approach for VTE prophylaxis using a 40 mg/day regimen may be improper for rehabilitation patient populations. The efficacy of fixed-dose enoxaparin prophylaxis is limited and may be influenced by renal function and weight. Patients who are hospitalized for rehabilitation are especially sensitive to bleeding or thrombotic events that can further complicate their recovery. For this reason, anti-Xa studies should be considered in certain patients, such as those who underweight, overweight and have suboptimal renal function.

Acute ischemic stroke (AIS), American Society of Haematology (ASH), anti-factor Xa (anti-Xa), antithrombin (AT), body mass index (BMI), creatinine clearance (CrCl), deep venous thrombosis (DVT), factor Xa (FXa), low molecular weight heparin (LMWH), pulmonary embolism (PE), serum creatinine (CR), sub-acute ischemic stroke (SAIS), spinal cord injury (SCI), unfractionated Heparin (UFH), venous thromboembolism (VTE)

Ethics approval and consent to participate: This study involved human participants, human blood samples and human data and was approved by the Institutional Ethics Committee on Human Research at the Loewenstein Rehabilitation Hospital (No. NCT103593291). The study was performed in accordance with relevant guidelines and regulations, including the Institutional Ethics Committee on Human Research at the Loewenstein Rehabilitation Hospital. Informed consent was obtained from all individual participants included in the study.

Consent for publication: Not applicable

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Funding: The authors did not receive support from any organization for the submitted work.

Authors' contributions: Amir Haim, Dvora Asher and Motti Ratmansky contributed to the study conception and design. Material preparation, data collection and analysis were performed by Orli Avnery, Kaifa Hashem, Harel Ben Zvi and Amir Haim. The first draft of the manuscript was written by Amir Haim and Hagay Amir and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements: Not applicable

Khan MT, Ikram A, Saeed O, Afridi T, Sila CA, Smith MS, et al. (2017) Deep vein thrombosis in acute stroke - a systemic review of the literature. Cureus 9:e1982.
Kong KH, Chua SG (2009) Deep vein thrombosis based on D-dimer screening in ischaemic stroke patients undergoing rehabilitation. Singapore Med J 50:971-5.
Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. (2016) Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 47:e98-e169.
Ye F, Bell LN, Mazza J, Lee A, Yale SH (2018) Variation in definitions of immobility in pharmacological thromboprophylaxis clinical trials in medical inpatients: a systematic review. Clin Appl Thromb Hemost 24:13-21.
Zhao Z, Tian Q, Zhang B (2021) Effects of rehabilitation nursing care on deep vein thrombosis of the lower limbs following spinal fractures. Am J Transl Res 13:1877-83.
Kim JT, Chun YS, Lee JK, Moon NJ, Yi DY (2020) Comparison of vessel density reduction in the deep and superficial capillary plexuses in branch retinal vein occlusion. Ophthalmologica 243:66-74.
Hon B, Botticello A, Kirshblum S (2020) Duplex ultrasound surveillance for deep vein thrombosis after acute traumatic spinal cord injury at rehabilitation admission. J Spinal Cord Med 43:298-305.
Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2:3198-225.
Liu LP, Zheng HG, Wang DZ, Wang YL, Hussain M, Sun HX, et al. (2014) Risk assessment of deep-vein thrombosis after acute stroke: a prospective study using clinical factors. CNS Neurosci Ther 20:403-10.
Prevention of Venous Thromboembolism in Individuals with Spinal Cord Injury: Clinical Practice Guidelines for Health Care Providers, 3rd ed.: Consortium for Spinal Cord Medicine (2016) Top Spinal Cord Inj Rehabil 22:209-40.
Teasell RW, Hsieh JT, Aubut JA, Eng JJ, Krassioukov A, Tu L (2009) Spinal Cord Injury Rehabilitation Evidence Review Research Team. Venous thromboembolism after spinal cord injury. Arch Phys Med Rehabil 90:232-45.
Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, et al. (2007) PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369:1347-55.
Weidner N, Müller OJ, Hach-Wunderle V, Schwerdtfeger K, Krauspe R, Pauschert R, et al. (2020) Prevention of thromboembolism in spinal cord injury -S1 guideline. Neurol Res Pract 2:43.
Alabed S, Belci M, Van Middendorp JJ, Al Halabi A, Meagher TM (2016) Thromboembolism in the sub-acute phase of spinal cord injury: a systematic review of the literature. Asian Spine J 10:972-81.
Sandercock PA, Leong TS (2017) Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev 4:CD000119.
Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42:1043-57.
Rakhra S, Martin EL, Fitzgerald M, Udy A (2020) The ATLANTIC study: Anti-Xa level assessment in trauma intensive care. Injury 51:10-4.
Pannucci CJ, Prazak AM, Scheefer M (2017) Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis. Am J Surg 213:1143-52.
Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064-83.
Vandiver JW, Ritz LI, Lalama JT (2016) Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations. J Thromb Thrombolysis 41:475-81.
Maurice-Dror C, Litvak M, Keren-Politansky A, Ackerman S, Haim N, Nadir Y (2020) Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin. J Thromb Thrombolysis 50:112-22.
Bara L, Planes A, Samama MM (1999) Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol. 104:230-40.
Baumgartner JM, McKenzie S, Block S, Costantini TW, Lowy AM (2018) Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. J Surg Res 221:183-9.
Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, et al. (2010) Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 68:874-80.
Cronin BJ, Godat LN, Berndtson AE, Pham A, Kolan S, Box K, et al. (2019) Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients. Burns 45:818-24.
Lin H, Faraklas I, Cochran A, Saffle J (2011) Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res 32:1-5.
Costantini TW, Min E, Box K, Tran V, Winfield RD, Fortlage D, et al. (2013) Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg 74:128-35.
Rojas L, Aizman A, Ernst D, Acuña MP, Moya P, Mellado R, Cerda J (2013) Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms. Thromb Res 132:761-4.
Millar JA (2012) The Cockroft and Gault formula for estimation of creatinine clearance: a friendly deconstruction. N Z Med J 125:119-22.
HermosIL Liquid Anti-Xa – 0020302601 (2021) Instrumentation Laboratory, a Werfen Company,
Sanofi Limited. Enoxaparin Sodium Injection I.P (Clexane) Approved Product Information. Updated 14 October 2018.
Robinson S, Zincuk A, Strøm T, Larsen TB, Rasmussen B, Toft P (2010) Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 14:R41.
Robinson S, Zincuk A, Larsen UL, Ekstrøm C, Nybo M, Rasmussen B, Toft P (2013) A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. Crit Care 17:R75.
Dybdahl D, Walliser G, Pershing M, Collins C, Robinson D (2019) Enoxaparin dosing for venous thromboembolism prophylaxis in low body weight patients. Clin Med Insights Blood Disord 12:1179545X19863814.
Ahuja T, Mousavi KM, Klejmont L, Desai S (2018) Enoxaparin dosing and antixa monitoring in specialty populations: a case series of renal-impaired, extremes of body weight, pregnant, and pediatric patients. P T 43:609-14.
Rodier SG, Bukur M, Moore S, Frangos SG, Tandon M, DiMaggio CJ, et al. (2021) Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting. Eur J Trauma Emerg Surg 47:145-51.
Singer GA, Riggi G, Karcutskie CA, Vaghaiwalla TM, Lieberman HM, Ginzburg E, et al. (2016) Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg 81:1101-8.

No competing interests reported.

Download PDF

Journal Publication

published 10 Jan, 2024

Read the published version in BMC Pharmacology and Toxicology →

Editorial decision: Major revision
09 Jun, 2023
Reviews received at journal
09 Jun, 2023
Reviews received at journal
07 Jun, 2023
Reviewers agreed at journal
28 May, 2023
Reviewers agreed at journal
26 May, 2023
Reviewers invited by journal
10 Mar, 2023
Editor assigned by journal
10 Mar, 2023
Editor invited by journal
27 Feb, 2023
Submission checks completed at journal
27 Feb, 2023
First submitted to journal
19 Feb, 2023

You are reading this latest preprint version

Enoxaparin for VTE thromboprophylaxis for inpatient rehabilitation care: assessment of the standard fixed dosing regimen

Status:

Journal Publication

Version 1

Abstract

Figures

Key Points

Introduction

Patients And Methods

Data Collection

Statistical analysis

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 1